Cargando…
Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation
Traditional Chinese medicine has shown great safety and efficacy in the treatment of heart failure (HF), whereas the mechanism remains unclear. In this study, the protective effect of Yixin-shu (YXS) capsules, a conventional medicine for various cardiovascular diseases, against myocardial ischemia-i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902134/ https://www.ncbi.nlm.nih.gov/pubmed/33643519 http://dx.doi.org/10.1155/2021/8049079 |
_version_ | 1783654501512642560 |
---|---|
author | Xiang, Changpei Zhang, Fangbo Gao, Jinhuan Guo, Feifei Zhang, Mao Zhou, Rui Wei, Junying Wang, Ping Zhang, Yi Zhang, Jingjing Yang, Hongjun |
author_facet | Xiang, Changpei Zhang, Fangbo Gao, Jinhuan Guo, Feifei Zhang, Mao Zhou, Rui Wei, Junying Wang, Ping Zhang, Yi Zhang, Jingjing Yang, Hongjun |
author_sort | Xiang, Changpei |
collection | PubMed |
description | Traditional Chinese medicine has shown great safety and efficacy in the treatment of heart failure (HF), whereas the mechanism remains unclear. In this study, the protective effect of Yixin-shu (YXS) capsules, a conventional medicine for various cardiovascular diseases, against myocardial ischemia-induced HF in rats was systematically investigated by RNA-seq technology. HF rats treated with YXS (0.8 or 1.6 g/kg/d, ig) for 6 weeks had significantly decreased brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) and collagen III and attenuated cardiac structure rupture and collagen deposition. Additionally, YXS treatment decreased the levels of interleukin-1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and lactate dehydrogenase (LDH) and TUNEL-positive rate and the nitrotyrosine staining, but increased levels of glutathione (GSH), total antioxidant capacity (T-AOC) activity, and mitochondrial membrane potential. Further experiments demonstrated that YXS restored Trx2 and inhibited the phosphorylation of JNK and p38, thereby improving cardiac function in the rats with HF. Silencing Trx2 decreased the protection of YXS in the response to H(2)O(2) as evidenced by the increase of caspase-3 activity and decrease of GSH level. Thus, YXS enhanced heart function and decreased myocardial damage through restoring Trx2 and inhibiting JNK and p38 activation in ischemia-induced HF. |
format | Online Article Text |
id | pubmed-7902134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-79021342021-02-26 Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation Xiang, Changpei Zhang, Fangbo Gao, Jinhuan Guo, Feifei Zhang, Mao Zhou, Rui Wei, Junying Wang, Ping Zhang, Yi Zhang, Jingjing Yang, Hongjun Oxid Med Cell Longev Research Article Traditional Chinese medicine has shown great safety and efficacy in the treatment of heart failure (HF), whereas the mechanism remains unclear. In this study, the protective effect of Yixin-shu (YXS) capsules, a conventional medicine for various cardiovascular diseases, against myocardial ischemia-induced HF in rats was systematically investigated by RNA-seq technology. HF rats treated with YXS (0.8 or 1.6 g/kg/d, ig) for 6 weeks had significantly decreased brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) and collagen III and attenuated cardiac structure rupture and collagen deposition. Additionally, YXS treatment decreased the levels of interleukin-1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and lactate dehydrogenase (LDH) and TUNEL-positive rate and the nitrotyrosine staining, but increased levels of glutathione (GSH), total antioxidant capacity (T-AOC) activity, and mitochondrial membrane potential. Further experiments demonstrated that YXS restored Trx2 and inhibited the phosphorylation of JNK and p38, thereby improving cardiac function in the rats with HF. Silencing Trx2 decreased the protection of YXS in the response to H(2)O(2) as evidenced by the increase of caspase-3 activity and decrease of GSH level. Thus, YXS enhanced heart function and decreased myocardial damage through restoring Trx2 and inhibiting JNK and p38 activation in ischemia-induced HF. Hindawi 2021-02-16 /pmc/articles/PMC7902134/ /pubmed/33643519 http://dx.doi.org/10.1155/2021/8049079 Text en Copyright © 2021 Changpei Xiang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Xiang, Changpei Zhang, Fangbo Gao, Jinhuan Guo, Feifei Zhang, Mao Zhou, Rui Wei, Junying Wang, Ping Zhang, Yi Zhang, Jingjing Yang, Hongjun Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation |
title | Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation |
title_full | Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation |
title_fullStr | Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation |
title_full_unstemmed | Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation |
title_short | Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation |
title_sort | yixin-shu capsules ameliorated ischemia-induced heart failure by restoring trx2 and inhibiting jnk/p38 activation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902134/ https://www.ncbi.nlm.nih.gov/pubmed/33643519 http://dx.doi.org/10.1155/2021/8049079 |
work_keys_str_mv | AT xiangchangpei yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT zhangfangbo yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT gaojinhuan yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT guofeifei yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT zhangmao yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT zhourui yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT weijunying yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT wangping yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT zhangyi yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT zhangjingjing yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation AT yanghongjun yixinshucapsulesamelioratedischemiainducedheartfailurebyrestoringtrx2andinhibitingjnkp38activation |